Endevica Bio

Executive Summary

Endevica Bio is a privately-held biotechnology company founded in 2018 and headquartered in Tulsa, Oklahoma. The company specializes in designing novel peptidomimetic therapeutics that mimic peptides but offer improved stability and bioavailability compared to traditional small molecules and biologics. Endevica's primary focus is on targeting the melanocortin system to address metabolic disorders, particularly obesity and cancer cachexia. By modulating melanocortin receptors, the company aims to develop therapies that can regulate appetite, energy expenditure, and muscle wasting, which are critical in these conditions. The melanocortin pathway is a validated target, and Endevica's peptidomimetic approach seeks to overcome the limitations of earlier peptide-based drugs, such as poor pharmacokinetics and limited oral bioavailability. Endevica Bio is currently in the preclinical to early clinical stage, with its lead candidate advancing toward Phase 1 clinical trials. The company has not yet disclosed specific pipeline details or trial timelines, but its platform has potential for multiple indications. As a private company, Endevica may rely on partnerships or funding to progress its programs. The near-term outlook hinges on successful IND filings, initiation of first-in-human studies, and possible collaborations with larger pharmaceutical companies interested in metabolic diseases. While still early-stage, Endevica's focus on a well-understood biological pathway and its innovative peptidomimetic technology position it as a potential player in the metabolic space.

Upcoming Catalysts (preview)

• Q4 2026Initiation of Phase 1 clinical trial for lead candidate70% success
• Q2 2027Presentation of preclinical data at a major metabolic conference80% success
• Q3 2027Announcement of strategic partnership or licensing deal40% success